Wolfgang Miesbach on Transforming Care for Women and Girls with Bleeding Disorders: Key Guidelines 2021–2024
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:
“Advancing Care for Women and Girls with Bleeding Disorders
The clinical landscape has transformed significantly through evidence-based guidelines (2021-2024), finally addressing historical gaps in care for this mainly unrecognized population:
2021 ISTH Nomenclature Revolution
Eliminated outdated ‘carrier’ terminology
Established 5 evidence-based categories from severe to asymptomatic women and girls with bleeding disorders
Improved diagnostic accuracy and research uniformity
2021 ASH/ISTH/NHF/WFH VWD Guidelines
Prioritized hormonal therapy and tranexamic acid over desmopressin for heavy menstrual bleeding
Set clear diagnostic thresholds: <0.30 IU/mL (regardless of bleeding) and <0.50 IU/mL (with bleeding)
2021 European Principles of Care
EAHAD and EHC established 10 comprehensive care principles
Promoted systematic screening across European centers
2024 NBDF MASAC Guidelines
Document 286: Most comprehensive update yet
Mandated iron deficiency screening even with normal hemoglobin
Addressed historical underdiagnosis gaps
Persistent Challenges:
Despite progress, women and girls with bleeding disorders remain systematically excluded from clinical trials, creating dangerous knowledge gaps that impact:
Diagnostic delays
Higher anemia & transfusion rates
Unnecessary hysterectomies
25% report severe reproductive decision impact
The path forward requires collaborative research and gender-specific treatment studies to truly close these healthcare disparities.”
Stay informed with Hemostasis Today.
-
Sep 2, 2025, 08:51Perioperative Direct Oral Anticoagulant (DOAC) Dosing: Insights Dr. Sthanu Subramanian
-
Sep 2, 2025, 08:49Why Polycythemia Vera Doesn’t Raise EPO Levels Explained by William Aird
-
Sep 2, 2025, 08:47SUGAR Trial in Heart BMJ: Stent Outcomes in Patients With Diabetes Under the Spotlight
-
Sep 2, 2025, 08:43Eltrombopag with Immunosuppressive Therapy Shows Promising Safety in Pediatric Severe Aplastic Anemia – Phase 2 ESCALATE Trial Results
-
Sep 2, 2025, 08:14Mirvat Alasnag Discusses OPTION-STEMI Findings Published in The Lancet
-
Sep 1, 2025, 15:31Low-Dose DOACs Reduce VTE Risk in Transplant-Ineligible Multiple Myeloma: Insights from the BENEFIT Trial
-
Sep 1, 2025, 07:39Flora Peyvandi: Reappraising Hemostasis Testing in Cirrhosis
-
Sep 1, 2025, 07:35Dario Bongiovanni Presents Milestone Discovery on Reticulated Platelets at ESC Congress 2025
-
Sep 1, 2025, 07:19Felice Gragnano: Clopidogrel vs Aspirin for Secondary Prevention in Coronary Artery Disease – Meta-Analysis Shows Superior MACCE Protection
-
Sep 1, 2025, 07:18Wolfgang Miesbach: New Research Reveals Clonogenic Hepatocytes as the Key Drivers of Liver Growth and Gene Therapy Success
-
Aug 29, 2025, 09:03Vasculearn Network: New 2025 High Blood Pressure Guidelines Are Here
-
Aug 18, 2025, 23:56Dr. Arun V. J Invites You to His Lecture on ‘AI and Data Sciences in Transfusion Medicine’ at the AI in Healthcare Conclave. Register now!
-
Aug 18, 2025, 23:50Safe and Efficient Thrombectomy with Artix System: Clinical Insights from Neil Desai and Colleagues
-
Aug 16, 2025, 14:42Mark Crowther Honors Davide Matino for Leading Promising Hemophilia Trial at McMaster University
-
Aug 14, 2025, 10:28Impressive 95% Clot Removal in a VTE Case: Symphony16F and Symphony24F Catheters
-
Sep 1, 2025, 08:09Wafik S. El-Deiry Opens Up on Recovery, Gratitude, and Book After Life-Changing Heart Surgery
-
Aug 31, 2025, 07:30Michael Albert: Being ‘Metabolically Healthy’ Doesn’t Eliminate Heart Disease Risk
-
Aug 31, 2025, 07:15Should 12-Month DAPT Be the Default After ACS? Mattia Galli Applauds Marco Valgimigli’s Talk
-
Aug 31, 2025, 07:10Ewa Fiorentino-Rozek on Blood Group Genotyping: Are We Ready for Routine Use?
-
Aug 30, 2025, 14:45Gordon’s Journey: 60 Years of Life After DVT Managed with Warfarin